This study is a proof of concept to determine if an investigational drug called LCQ908 can reduce triglyceride levels and lessen cardiovascular risk in people with cardiovascular disease.
Eligible participants will be between 40 and 80 years old, currently use a daily anti-cholesterol medication, and have a history of heart disease. Enrolled volunteers will come to the Duke Clinical Research Unit for 6 visits over the course of approximately 12 weeks. Two of the visits will require an overnight stay, and another visit will require a cardiac MRI to be performed.
Each participant will take part in two separate treatment periods. One of the treatment periods will involve the use of the active study drug, and the other treatment period will involve the use of a placebo.
Enrolled participants will be compensated up to $2,000 for full completion of the study.
For more information, please call the Duke Clinical Research Unit at 919-613-6246 or email us at email@example.com.
For more information, contact Duke Clinical Research Unit at 919-613-6246.